Take advantage of the LCD and procedure to diagnosis lookup to find information in current and draft LCDs.
Investigational device exemption (IDE) process for studies approved by the Centers for Medicare & Medicaid Services (CMS)
The Centers for Medicare & Medicaid Services (CMS) made changes to the IDE regulations (42 CFR § 405 Subpart B). CMS outlined criteria for coverage of IDE studies and changed from local Medicare administrative contractor (MAC) review and approval of IDE studies to a centralized review and approval of IDE studies.
Review answers to frequently-asked questions regarding clinical trials and device coverage.
Medicare covers the use of devices that are "reasonable and necessary for the diagnosis and treatment of an injury or illness or to improve the functioning of a malformed body member.”
Medicare may provide extended coverage and reimbursement for certain investigational devices and services related to the use of those devices. Coverage is contingent upon meeting regulatory criteria and Florida medical director's approval.
Medicare may provide coverage and reimbursement for certain investigational devices and services related to the use of those devices. Coverage is contingent upon meeting regulatory criteria and contractor's approval.
CAS studies are limited to FDA-approved carotid artery stents (CAS). No other post-approval studies should be submitted to First Coast Service Options for approval.
When submitting requests for continuations of your participation in the post-approval or a 510K for carotid artery stenting (CAS) study, please update your file with First Coast Service Options Inc. (First Coast).
FCSO may consider coverage of a humanitarian use device, intended to benefit a small patient population, when the provider follows the specific guidelines and submits the appropriate documentation.
The clinical trial coding and cost form is required when submitting a request for a clinical trial or a clinical trial Extension.
Change request 9674 implements revenue code 0815, which is used when the hospital identifies stem cell acquisition charges for allogeneic bone marrow/stem cell transplants separately. [MM9674]
This article addresses billing issues related the stem cell transplants, which clarifies what place of services providers should be billing. [SE1624]
A listing of useful links is provided regarding devices and clinical trial processes.
Notification of Centers for Medicare & Medicaid Services (CMS) approval to First Coast Service Options for TAVR/TAMR
Important information notifying users of the requirements for approval of transcatheter aortic valve replacement and transcatheter mitral valve repair (TAVR/TMVR) studies.
First Coast Service Options (First Coast) strives to ensure that the information available on our provider website is accurate, detailed, and current. Therefore, this is a dynamic site and its content changes daily. It is best to access the site to ensure you have the most current information rather than printing articles or forms that may become obsolete without notice.